-
Olaparib, sold
under the
brand name Lynparza, is a
medication for the
maintenance treatment of BRCA-mutated
advanced ovarian cancer in adults. It is a...
- for long-term
neurodegenerative diseases.
Olaparib: In December, 2014, the EMA and US FDA
approved olaparib as
monotherapy (at 400 mg
taken twice per...
-
treatments for
astrocytoma and as the first-line
treatment for glioblastoma.
Olaparib in
combination with
temozolomide demonstrated substantial clinical activity...
- mutations.
Talazoparib is
similar to the
first in
class PARP inhibitor,
olaparib. The most
common adverse reactions of any
grade were fatigue, anemia, nausea...
- small-molecule
drugs or
monoclonal antibodies, and PARP
inhibitors such as
olaparib.
Other therapies include hyperthermia, immunotherapy,
photodynamic therapy...
-
Fleming GF, et al. (October 2014). "Combination
cediranib and
olaparib versus olaparib alone for
women with
recurrent platinum-sensitive
ovarian cancer:...
-
metastases due to SCLC. In a
clinical trial of 50 patients, a
combination of
olaparib and
temozolomide in
relapsed small-cell lung
cancer yielded an overall...
- bromide/formoterol
Goserelin Isosorbide mononitrate Metoprolol Motavizumab Olaparib Omeprazole Osimertinib Palivizumab Propofol Quetiapine Ravulizumab Roflumilast...
- Carboplatin/Pa****axel
Followed by
Maintenance Durvalumab With or
Without Olaparib as First-Line
Treatment for
Advanced Endometrial Cancer: The
Phase III...
-
clinical trials, navitoclax, and gossypol. PARP
inhibitors (e.g. FDA
approved olaparib, rucaparib,
niraparib and talazoparib) PI3K
inhibitors (e.g. perifosine...
